Financial Services

TIME's honor for AI's creators reveals a hidden truth: the digital revolution's massive energy and hardware needs are supercharging the race for minerals.

KB Home's sixth consecutive corporate responsibility award offers a surprising blueprint for the healthcare sector. Can a homebuilder's ESG strategy pay off for pharma?

CardCash's record November reveals a major shift in consumer behavior, where shoppers are using discounted gift cards as a tool to fight inflation.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

Impressive drill results from Lapon Canyon are turning heads, but the discovery of monzonite-hosted gold suggests a much larger story is unfolding.

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

With a new $6.5M investment, Double is tackling the accounting talent crisis with AI that empowers professionals, not replaces them. Here's why.

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

As national banks celebrate rising satisfaction from digital innovation, a new study reveals a silent crisis: older customers are being left behind.

The EU's landmark decision to ease rules on New Genomic Techniques opens a multi-billion dollar market, and ag-tech pioneer Cibus is ready to cash in.

Apollo Silver plans to revive a massive California silver deposit, aligning with US strategic goals. Can it overcome technical and environmental hurdles?

As agencies retool for a complex market, Bastion's appointment of a cultural PR expert highlights a critical shift for pharma and beyond.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.

Biotech startup Bio Usawa appoints a world-renowned health expert to lead its access board, betting its entire business model on making advanced drugs affordable.

Advantest's T2000 AiR2X isn't just new hardware. It's a calculated move to solve the chip industry's legacy pains and efficiency demands.

How Circus SE's autonomous robot is set to revolutionize corporate dining, tackling food waste and augmenting the workforce at a top auto plant.

CEAT Specialty's new OTR tyre isn't just rubber—it's a strategic play for India's trillion-dollar infrastructure push, blending tech and market savvy.